InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: atonewith PPHM post# 212871

Thursday, 03/26/2015 11:39:06 AM

Thursday, March 26, 2015 11:39:06 AM

Post# of 346052

Bio, Wasn't March 2014 when we had those 2 36 mil days?
AtonewithPPHM



Yes... very true and I am just trying to dig deeper and out of the box to find out what other possibilities could have been set up at that time.

For one, I think Ben Kramer-Miller is part of it but like I said before... I check every single path and some lead no where and some surprisingly, connect in some way.

I don't believe Ben Kramer-Miller mentioned Peregrine Pharmaceuticals in his article for no reason at all and if XON is the stock to own for the next decade and if some with XON P53 etc knows that PS Targeting is required, maybe Ben Kramer-Miller should dig deeper and he may think that if XON is the stock to own for the next decade, then Peregrine Pharmaceuticals would be the stock to own for the next two decades or at minimum until PS Targeting patents begin to expire. Of course, by that time.... Peregrine and PS Targeting revenues will bring in much money in order to diversify in all directions outside of the traditional Big Pharma like business.

Ben Kramer-Miller Articles ... a reminder to all for the patent filing date and publication date:

Application Number:
14/204914
Publication Date:
02/12/2015
Filing Date:
03/11/2014

Full patent description:
http://investorshub.advfn.com/boards/replies.aspx?msg=112089063

Ben Kramer-Miller:

May 6, 2014
..
..
Regarding the second one, we know that Peregrine is working towards a cure for cancer. But will it find one? Even if it does, who’s to say that Peregrine will be first or that its cure will be accepted by the FDA? If you buy Peregrine shares based on the thesis I provide, and if you are right, you will probably make several multiples on your initial investment. But if Peregrine fails, then your investment goes to zero. Also keep in mind that you are not the only one betting one way or another on Peregrine’s success. What gives you an advantage over the scientists and doctors that the experts on Wall Street can easily afford to hire? The fact of the matter is that Peregrine is speculative — if you buy shares, you are betting that a future binary event will have a specific outcome.

http://www.cheatsheet.com/business/dont-gamble-with-your-future-invest-dont-speculate.html/?a=viewall



Feb 10, 2015

Miller also explains why he thinks Intrexon (XON) could be the stock to own for the next decade.

http://www.gurufocus.com/news/315541/bill-miller-identifies-what-could-be-the-stock-of-the-decade



--------------------------------------------------------

Time to connect some dots with Peregrine employees/KOL's , Sunil Chada and finance guys and BP affiliations and much more... unfortunately, I need to head back to California for the 2nd time in like 5 or 6 years and the posts will be short and sweet but getting closer.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News